All research and development (R&D) at Vernalis is focused with a goal of developing novel medicines that are commercially attractive. Through its research, the company has built up a development pipeline focused on central nervous (CNS) disorders and oncology.
Pain Franchise
Frova® is a 5-HT1B/1D receptor agonist approved in the United States and Europe for the oral treatment of migraine.
Frova® is a 5-HT1B/1D receptor agonist approved for the oral treatment of migraine. Frova® has also completed Phase III trials for the short-term prevention of Menstrual Migraine (MM) and an sNDA was filed with the FDA in July 2006
V1003 is a potent analgesic, tailored for the management of post-operative pain in hospital and home settings.
V3381 is a novel drug candidate that is being developed for neuropathic pain.
Neurology Franchise
Parkinson's disease
Apokyn® (apomorphine hydrochloride injection) is approved in the United States for the acute, intermittent treatment of hypomobility, "off" episodes associated with advanced Parkinson’s disease.
V1512 is an innovative, patented effervescent formulation combining levodopa (L-dopa) methyl-ester, a more soluble form of levodopa, and carbidopa.
V2006 is an adenosine A2A receptor antagonist in development as a potential novel treatment for Parkinson's disease.
Stroke
V10153 is a novel recombinant thrombolytic protein which is being developed for the treatment of ischaemic stroke.
Other Franchises
The MMPI programme is focused upon identifying selective inhibitors of metalloproteases believed to be involved in inflammatory and immune disorders including multiple sclerosis.
V24343 is a potent and selective cannabinoid receptor antagonists being investigated as a novel treatment for obesity.
Hsp90 is a novel drug target, inhibition of which is believed to have significant potential in the treatment of a broad range of cancers.
Product Pipeline
The discovery of novel medicines to treat human disease is the cornerstone of our business. To find out more details of the conditions we are seeking to treat - view our product pipeline.